Predicting lymphovascular invasion in pancreatic cancer patients before surgery
Development and Validation of a Preoperative Model to Predict the Lymphovascular Invasion of Pancreatic Ductal Adenocarcinoma: a Multicenter Retrospective Study
Tianjin Medical University Cancer Institute and Hospital · NCT05997147
This study is trying to create a tool that helps doctors predict if pancreatic cancer patients will have lymphovascular invasion before they have surgery, which could guide their treatment choices.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1009 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital (other) |
| Locations | 1 site (Tianjin, Tianjin) |
| Trial ID | NCT05997147 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop a preoperative model to predict lymphovascular invasion (LVI) in patients diagnosed with pancreatic ductal adenocarcinoma (PDAC). By analyzing data from patients at three tertiary hospitals, the researchers will use univariate and multivariate logistic regression to identify independent predictors of LVI. A nomogram will be created based on these findings, and its predictive accuracy will be evaluated using ROC curves and calibration plots. The study seeks to provide a tool that could help guide treatment decisions for PDAC patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have been pathologically diagnosed with PDAC and are scheduled for curative surgery.
Not a fit: Patients with distant metastasis, those who have received neoadjuvant therapy, or those with a survival time of less than one month may not benefit from this study.
Why it matters
Potential benefit: If successful, this model could help identify patients who may benefit from neoadjuvant therapy, potentially improving their survival outcomes.
How similar studies have performed: While predictive models for cancer prognosis are common, this specific approach to predicting LVI in PDAC is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who were pathologically diagnosed as PDAC and received curative surgery. Exclusion Criteria: * Patients with distant metastasis; Patients who received neoadjuvant therapy; Patients with a survival time of less than 1 month.
Where this trial is running
Tianjin, Tianjin
- Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin, China (RECRUITING)
Study contacts
- Study coordinator: Jihui Hao, Dr
- Email: haojihui@tjmuch.com
- Phone: +8618622221120
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Predictive Cancer Model, Pancreas Cancer